Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00037180 · ClinicalTrials.gov registry record · Phase 2
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 212
- Enrollment target
NCT00037180 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 212 participants.
The verdict
NCT00037180, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 212 participants
- Enrollment target
Study Summary
The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approved treatment for patients with metastatic colorectal cancer is repeated cycles of chemotherapy consisting of a combination of irinotecan (also known as CPT-11, Camptosar), 5-fluorouracil (also known as 5FU), and leucovorin (also known as LV). Preclinical data from animal models suggest that the investigational drug may offer an effective means for preventing CPT-11/5FU/LV-induced diarrhea. It is also hypothesized that the investigational drug-mediated anti-angiogenesis could induce a favorable tumor response.
Interventions
- DRUG Leucovorin
- DRUG Celecoxib
- DRUG Irinotecan
- DRUG 5-fluorouracil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2002-04 |
| Est. Completion | 2003-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00037180
The ClinicalTrials.gov registry entry for NCT00037180 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT00037180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00037180 about?
NCT00037180 is a clinical study titled "For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy". The Diarrhea Prevention with an investigational drug trial, will evaluate whether adding an investigational drug to the standard treatment for advanced colorectal cancer can reduce the amount of diarrhea a patient experiences. The standard and approved treatment for patients with metastatic colorect...
What is the current status of trial NCT00037180?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 212 participants. The study started on 2002-04. Estimated completion is 2003-01.
What interventions are being tested in trial NCT00037180?
The interventions under investigation include: Leucovorin (DRUG), Celecoxib (DRUG), Irinotecan (DRUG), 5-fluorouracil (DRUG).
Who is sponsoring clinical trial NCT00037180?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.